C5 and anemia (phenotype): In May 2021, the company (Apellis Pharmaceuticals/Sobi) provided a submission to NICE describing the use of pegcetacoplan (within the context of its licensed indication) in patients with PNH who had uncontrolled anaemia after treatment with a C5 inhibitor for a period of ≥ 3 months.